Skip to main content
Livermore
Livermore
ZHEN

Lindbrook Capital, LLC

SEC CIK
0001767045
Latest filing
May 5, 2025

ADAPY holding history

Adaptimmune Therapeutics PLC in every 13F filed by Lindbrook Capital, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ADAPY overviewAll 13F holders of ADAPYFull Q1 2025 holdings

Shares (Q1 2025)
4,610
Value
$908
% of portfolio
<0.1%
Quarters held
15
Since Q1 2021
Holdings of ADAPY by Lindbrook Capital, LLC, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q1 20254,610$908<0.1%00.0%UnchangedHolders
Q4 20244,610$2.48K<0.1%−237−4.9%ReducedHolders
Q3 20244,847$4.61K<0.1%+237+5.1%AddedHolders
Q2 20244,610$4.49K<0.1%−2,135−31.7%ReducedHolders
Q1 20246,745$10.7K<0.1%+2,135+46.3%AddedHolders
Q4 20234,610$3.66K<0.1%00.0%UnchangedHolders
Q3 20234,610$3.60K<0.1%00.0%UnchangedHolders
Q2 20234,610$4.26K<0.1%+4,610NewHolders
Q4 20220$00.0%−3,084−100.0%Sold outHolders
Q3 20223,084$3.00K<0.1%+2,766+869.8%AddedHolders
Q2 2022318$1.00K<0.1%+139+77.7%AddedHolders
Q1 2022179$00.0%−3,096−94.5%ReducedHolders
Q4 20213,275$12.0K<0.1%−5,392−62.2%ReducedHolders
Q3 20218,667$45.0K<0.1%+2,057+31.1%AddedHolders
Q2 20216,610$28.0K<0.1%+5,000+310.6%AddedHolders
Q1 20211,610$9.00K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.